This is a preview of subscription content, log in via an institution to check access.
References
Zielinski C, Beslija S, Mrsic Z, et al. Gemcitabine/Epirubicin/Paclitaxel versus 5-fluorouracil/epirubicin/cyclophosphamide as first-line chemotherapy in metastatic breast cancer: A Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial. J Clin Oncol, 23: 1401–1408, 2005
Brodowicz T, Krzakowski M, Zwitter V, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. J IASLC, 52: 155–163, 2006
Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine versus gemcitabine alone in advanced pancreatic cancer. A randomized phase III trial. J Clin Oncol, 25: 2212–2217, 2007
Kahán S, Spanik S, Wagnerova M, et al. A randomized, open-label CECOG phase II study of dose-dense FEC 75 vs FEC 90 as adjuvant therapy in early breast cancer patients. Eur J Cancer, 5(Suppl 4): 211, 2007 (abstr 2095)
Ciuleanu T, Scheithauer W, Kurteva G, et al. A randomized, open-label phase II study evaluating the efficacy and safety of FOLFOX-6 + cetuximab versus FOLFIRI + cetuximab as first-line therapy in patients with metastatic colorectal cancer. Eur J Cancer, 5(Suppl 4): 249, 2007 (abstr 3046)
Zielinski C, Beinert T, Crawford J, et al. Consensus on medical treatment of non-small-cell lung cancer, update 2004. Lung Cancer, 50: 129–137, 2005
Besilja S, Bonneterre J, Burstein H, et al. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol, 18(2): 215–225, 2007 (Epub 2006 July 10)
Rights and permissions
About this article
Cite this article
Zielinski, C. memo – New official Journal of CECOG. memo 1, 2 (2008). https://doi.org/10.1007/s12254-008-0002-9
Issue Date:
DOI: https://doi.org/10.1007/s12254-008-0002-9